Keybank National Association OH Sells 7,337 Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN)

Share on StockTwits

Keybank National Association OH cut its holdings in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 31.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,701 shares of the specialty pharmaceutical company’s stock after selling 7,337 shares during the period. Keybank National Association OH’s holdings in Supernus Pharmaceuticals were worth $520,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SUPN. Financial Gravity Wealth Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 1st quarter valued at $44,000. Bremer Bank National Association acquired a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at about $94,000. Adams Diversified Equity Fund Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at about $200,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at about $204,000. Finally, Diversified Trust Co acquired a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at about $208,000. Institutional investors and hedge funds own 98.93% of the company’s stock.

Shares of SUPN stock opened at $27.43 on Wednesday. The firm has a 50 day moving average price of $31.13 and a two-hundred day moving average price of $34.48. The company has a quick ratio of 2.53, a current ratio of 2.72 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $1.44 billion, a PE ratio of 13.42, a price-to-earnings-growth ratio of 0.93 and a beta of 1.54. Supernus Pharmaceuticals Inc has a 12-month low of $26.90 and a 12-month high of $51.38.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.05. Supernus Pharmaceuticals had a net margin of 25.66% and a return on equity of 22.36%. The company had revenue of $104.70 million during the quarter, compared to the consensus estimate of $109.67 million. During the same period in the previous year, the business earned $0.57 earnings per share. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. As a group, research analysts expect that Supernus Pharmaceuticals Inc will post 2.2 EPS for the current year.

Several analysts have issued reports on the company. Cantor Fitzgerald set a $60.00 price target on Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 8th. Mizuho reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, August 7th. Stifel Nicolaus set a $55.00 price target on Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 7th. Cowen set a $50.00 price target on Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, Zacks Investment Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 16th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $54.43.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Featured Story: What is a price target?

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Energy Income Partners LLC Buys 39,795 Shares of Mplx Lp
Energy Income Partners LLC Buys 39,795 Shares of Mplx Lp
Chesapeake Utilities Co.  Stock Position Decreased by Energy Income Partners LLC
Chesapeake Utilities Co. Stock Position Decreased by Energy Income Partners LLC
Family Management Corp Sells 4,840 Shares of Nuveen Municipal Value Fund Inc
Family Management Corp Sells 4,840 Shares of Nuveen Municipal Value Fund Inc
Energy Income Partners LLC Sells 21,934 Shares of IDACORP Inc
Energy Income Partners LLC Sells 21,934 Shares of IDACORP Inc
PGIM Global Short Duration Hgh Yd Fd Inc  Shares Bought by Family Management Corp
PGIM Global Short Duration Hgh Yd Fd Inc Shares Bought by Family Management Corp
Energy Income Partners LLC Sells 131,879 Shares of WEC Energy Group Inc
Energy Income Partners LLC Sells 131,879 Shares of WEC Energy Group Inc


© 2006-2019 Ticker Report